VICTRELIS Drug Patent Profile

Which patents cover Victrelis, and when can generic versions of Victrelis launch?

Victrelis is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-seven patent family members in seventeen countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

DrugPatentWatch^® Generic Entry Outlook for Victrelis

Victrelis was eligible for patent challenges on May 13, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 11, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VICTRELIS

International Patents:	27
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	9
Patent Applications:	2,692
DailyMed Link:	VICTRELIS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VICTRELIS

Constraining patent/regulatory exclusivity:

7,772,178

NDA:

202258

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VICTRELIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hoffmann-La Roche
Slotervaart Hospital	Phase 2
Onze Lieve Vrouwe Gasthuis	Phase 2

See all VICTRELIS clinical trials

US Patents and Regulatory Information for VICTRELIS

VICTRELIS is protected by two US patents.

This potential generic entry date is based on patent 7,772,178.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011		DISCN	No	No	7,772,178		Y
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011		DISCN	No	No	8,119,602

Expired US Patents for VICTRELIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011	7,012,066
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011	RE43298

EU/EMA Drug Approvals for VICTRELIS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp Dohme Ltd	Victrelis	boceprevir	EMEA/H/C/002332Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.	Withdrawn	no	no	no	2011-07-18

International Patents for VICTRELIS

When does loss-of-exclusivity occur for VICTRELIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VICTRELIS around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	140710	NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
Mexico	PA03000627	NUEVOS PEPTIDOS COMO INHIBIDORES DE PROTEASA SERINA-NS3 DEL VIRUS DE LA HEPATITIS C. (NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS.)
Taiwan	200716157	Pharmaceutical formulations and methods of treatment using the same
New Zealand	563365	Combination of HCV protease inhibitors with a surfactant

Supplementary Protection Certificates for VICTRELIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1385870	300506	Netherlands		PRODUCT NAME: BOCEPREVIR, OF EEN ENANTIOMEER, STEREOISIOMEER, ROTAMEER, TAUTOMEER OF RACEMAAT VAN DIE VERBINDING, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/704/001 20110718
1385870	C01385870/01	Switzerland		PRODUCT NAME: BOCEPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 62105 31.10.2011
1385870	C300506	Netherlands		PRODUCT NAME: BOCEPREVIR, OF EEN ENANTIOMEER, STEREOISIOMEER, ROATMEER, TAUTOMEER OF RACEMAAT VAN DIE VERBINDING, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/704/001 20110718
1385870	C 2011 014	Romania		PRODUCT NAME: BOCEPREVIR(1R,2S,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[(2S)-2[[[(1,1-DIMETILETIL)AMINO]CARBONIL]AMINO]-3,3-DIMETIL-1-OXOBUTIL]-6,6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/704/001; DATE OF NATIONAL AUTHORISATION: 20110718; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/704/001; DATE OF FIRST AUTHORISATION IN EEA: 20110718

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: VICTRELIS

Last updated: July 27, 2025

Introduction

VICTRELIS (boceprevir), developed by Merck & Co., Inc., marked a significant milestone as an oral NS3/4A protease inhibitor designed to treat chronic hepatitis C virus (HCV) infection, particularly genotype 1. Since its FDA approval in 2011, VICTRELIS has played a pivotal role in the evolving landscape of HCV therapy, driven by changing market dynamics, competitive pressures, and innovations in antiviral treatments. This analysis explores the key factors shaping VICTRELIS’s market trajectory and its financial implications within the broader context of HCV therapeutics.

---

Market Overview and Evolution

Initial Market Entry and Early Adoption

Upon approval in May 2011, VICTRELIS quickly entered a burgeoning HCV treatment market characterized by the demand for more effective therapies. It was positioned as part of the first-wave direct-acting antivirals (DAAs), introducing the concept of interferon-based triple therapy (with peginterferon and ribavirin). The drug’s mechanism, targeting the viral protease, offered significant improvements over previous regimens, boosting sustained virologic response (SVR) rates.

Initial adoption was rapid among hepatitis specialists, enticed by the promising efficacy shown in clinical trials. The drug’s label broadened to include certain HCV genotypes and specific patient populations, further expanding its utilization.

Market Challenges and Competitive Pressures

However, VICTRELIS’s market share faced immediate competitive threats from newer agents. Sofosbuvir (Sovaldi), introduced by Gilead Sciences in 2013, revolutionized HCV management with higher cure rates, shorter treatment durations, and fewer side effects. These advantages prompted a swift shift in prescribing patterns, diminishing VICTRELIS’s market dominance.

Simultaneously, the advent of interferon-free combinations — notably Gilead’s Harvoni (ledipasvir/sofosbuvir) and later Epclusa — rendered interferon-based triple therapy obsolete, directly impacting VICTRELIS’s sales.

Regulatory and Patent Considerations

Merck’s patent on boceprevir faced expiration challenges, inviting generic competition from biosimilars and generic manufacturers. Although VICTRELIS remained on the market, the generic threat created downward pressure on prices and profitability.

A strategic response involved off-label expansion into combination therapies and niche markets, though these initiatives had limited impact compared to the dominant market trends.

---

Market Dynamics Analysis

Key Drivers

• Innovation in HCV therapies: The rapid development and approval of highly effective, interferon-free regimens directly impacted VICTRELIS’s market share.
• Pricing and reimbursement landscape: With newer drugs commanding higher prices relative to older regimens, payers preferred these for their superior tolerability and efficacy.
• Regulatory approvals: Expanding indications and evolving guidelines influenced prescribing behaviors but often favored newer therapies.
• Global market variability: VICTRELIS’s availability in emerging markets provided some revenue streams amid declining demand in mature markets.

Constraints and Limitations

• Limited efficacy in resistant HCV strains: VICTRELIS’s constraints included suboptimal response rates in certain patient subsets compared to newer DAAs.
• Side effect profiles: Higher adverse events associated with protease inhibitors like anemia and rash led to decreased appeal among clinicians and patients.
• Market saturation: The global push toward eradication and simplified regimens reduced the overall demand for interferon-based therapies.

---

Financial Trajectory and Revenue Outlook

Historical Revenue Trends

At its peak, VICTRELIS generated substantial revenues for Merck. In 2012, shortly after launch, annual sales approached several hundred million dollars globally. However, subsequent years saw a steep decline.

By 2015, U.S. sales had declined sharply, with Merck reporting that VICTRELIS was no longer a top contributor to revenue within its antiviral portfolio. Declining sales reflected both market saturation and the emergence of superior therapeutic options.

Current and Future Revenue Considerations

As of the latest available data (2022–2023), VICTRELIS’s revenue contribution remains minimal, primarily existent in certain niche markets or regions where newer agents are less accessible. The patent expiration and generic competition further threaten sustained revenue streams, positioning VICTRELIS as a legacy drug.

Forecasts predict continued erosion of revenues over the next five years, barring new indications or formulation innovations (e.g., fixed-dose combinations including boceprevir). Merck’s strategic focus appears to have shifted toward next-generation antivirals and broader antiviral platforms.

---

Market and Financial Opportunities

Although VICTRELIS’s direct market role diminishes, opportunities persist in:

• Biosimilar development: Potential for biosimilar entrants can affect remaining sales.
• Niche indications: Rare patient populations or resistant HCV strains may sustain minimal demand.
• Combination therapy research: Exploring VICTRELIS within innovative, multi-drug regimens, especially in contexts with limited access to newer DAAs.

---

Conclusion

The market dynamics for VICTRELIS exemplify the rapid innovation cycle in antiviral therapy, highlighting how a once-promising drug can rapidly become obsolete due to technological advancements and shifting payer preferences. Financially, the drug’s trajectory shifted from robust sales to a declining plateau following the advent of superior, interferon-free regimens. Its case underscores the importance for pharmaceutical companies to anticipate regulatory, competitive, and scientific developments to safeguard product lifecycle and revenue streams.

---

Key Takeaways

• Early dominance followed by swift obsolescence: VICTRELIS initially captured a significant market share but quickly lost traction to newer DAAs.
• Innovation drives market shifts: The development of interferon-free therapies fundamentally transformed HCV treatment, diminishing VICTRELIS’s commercial viability.
• Patent expiry and competition influence profitability: Generic threats and biosimilars pressure prices and erode revenue.
• Future prospects are limited: VICTRELIS’s role in the pharmaceutical landscape will likely continue declining absent new indications or formulations.
• Strategic pivots are essential: Companies must adapt swiftly to scientific and regulatory evolutions to maintain competitive relevance.

---

FAQs

1. Why did VICTRELIS lose market share rapidly after its approval?
The emergence of highly effective, interferon-free oral regimens like Gilead’s Harvoni offered higher cure rates, shorter treatment durations, and fewer side effects, overshadowing VICTRELIS’s benefits and leading to swift market displacement.

2. Are there ongoing markets where VICTRELIS remains relevant?
Yes, in select regions with limited access to newer DAAs and in niche patient populations resistant to other treatments, VICTRELIS may still have limited use, but overall demand is negligible.

3. What is the financial outlook for VICTRELIS in the next five years?
Expect continued revenue decline, accelerated by patent expiration, generic competition, and the dominance of newer therapies. The drug’s contribution to Merck’s antiviral revenues is expected to be minimal.

4. Could VICTRELIS be incorporated into future combination therapies?
Potentially, but given the availability of more potent, safer, and simpler options, its role in new combination regimens is unlikely unless addressing specific unmet needs.

5. How has the patent landscape affected VICTRELIS’s market?
Patent expiration opened the market to biosimilars and generics, exerting downward pressure on pricing and further reducing the drug’s profitability and market share.

---

Sources

[1] U.S. Food & Drug Administration. VICTRELIS (boceprevir) FDA Approval. 2011.
[2] Merck & Co. Annual Reports and Financial Statements, 2011–2022.
[3] Gilead Sciences. Hepatitis C Virus (HCV) Market Review Reports, 2020–2023.
[4] IQVIA Data on HCV Treatments.
[5] MarketWatch and EvaluatePharma. Pharmaceutical Sales Data, 2010–2022.